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Abstract
Fluoropyrimidines (5-fluorouracil, capecitabine) are the mainstay chemotherapeutic agents for the 
treatment of many types of cancer. Metabolism of fluoropyrimidines requires dihydropyrimidine 
dehydrogenase (DPD encoded by the DPYD gene) and reduced or absent activity of this enzyme 
can result in severe and sometimes fatal toxicity. Evidence and therapeutic recommendations are 
presented for DPYD genotype-directed dosing of fluoropyrimidines. This document is an update 
to the 2013 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for DPYD 
genotype and fluoropyrimidine dosing (updates available at https://cpicpgx.org/guidelines/
guideline-for-fluoropyrimidines-and-dpyd/).
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INTRODUCTION
The purpose of this guideline is to provide information for the interpretation of clinical 
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to 
guide dosing of fluoropyrimidines (5-fluorouracil, capecitabine, and tegafur). Detailed 
guidelines for the use of fluoropyrimidines, their clinical pharmacology (1) as well as 
analyses of cost-effectiveness are beyond the scope of this document. The Clinical 
Pharmacogenetics Implementation Consortium (CPIC) guidelines consider the situation of 
patients for which genotype data are already available (2) (updates available at https://
cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).
FOCUSED LITERATURE REVIEW
A systematic literature review focused on DPYD genotype and 5-fluorouracil, capecitabine 




DPYD, the gene encoding dihydropyrimidine dehydrogenase (DPD), the rate-limiting 
enzyme for fluoropyrimidine catabolism, spans 950kb on chromosome 1p22 with 4399 
nucleotides in 23 coding exons (3). Numerous genetic variants in DPYD are known that alter 
the protein sequence or mRNA splicing (see DPYD Allele Frequency Table (4)). Some of 
these variants, based on current knowledge, do not affect DPD activity in a clinically 
relevant manner (e.g., c.85T>C, *9A, rs1801265, p.C29R; c.1627A>G, *5, rs1801159, 
p.I543V; c.2194G>A, *6, rs1801160, p.V732I), whereas others result in reduced enzyme 
function. In the context of 5-fluorouracil, four decreased function DPYD variants are of 
primary relevance due to their population frequency and established impact on enzyme 
function and toxicity risk: c.1905+1G>A (rs3918290, also known as DPYD*2A, 
DPYD:IVS14 + 1G>A), c.1679T>G (rs55886062, DPYD *13, p.I560S), c.2846A>T 
(rs67376798, p.D949V), and c.1129–5923C>G (rs75017182, HapB3). Of these variants, c.
1905+1G>A and c.1679T>G have the most deleterious impact on DPD activity, whereas c.
2846A>T and c.1129–5923C>G result in moderately reduced DPD activity (see further 
details below in “Linking genetic variability to variability in drug-related phenotypes”).
The most well-studied DPYD variant, c.1905+1G>A (*2A), is located at the intron 
boundary of exon 14 and results in skipping of the entire exon and a non-functional protein 
(5). The variant c.1129–5923C>G, located deep in intron 10, introduces a cryptic splice site 
and the partial production of a non-functional transcript (6). This single nucleotide 
polymorphism (SNP) is the likely underlying causal variant of a DPYD haplotype (HapB3) 
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spanning intron 5 to exon 11 (7). The synonymous variant c.1236G>A (rs56038477) is in 
perfect linkage disequilibrium with c.1129–5923C>G (r2 = 1.0, D’=1.0 in 1000 Genomes 
Project) and thus a proxy for this variant in Europeans. The variants c.1679T>G and c.
2846A>T are missense mutations that affect protein function (8).
In Europeans, HapB3 with c.1129–5923C>G is the most common decreased function DPYD 
variant (see DPYD Allele Frequency Table (4)) with carrier frequencies of 4.1–4.8%, 
followed by c.1905+1G>A (carrier frequency: 1–1.2%) and c.2846A>T (carrier frequency: 
0.8–1.4%). Considering all four variants combined, ~7% of Europeans carry at least one 
decreased function DPYD variant. In individuals with African ancestry, the decreased 
function variant c.557A>G (rs115232898, p.Y186C) is relatively common (~5% carrier 
frequency). Most other DPYD variants of phenotypic consequence are very rare 
(summarized in the DPYD Allele Frequency Table (4)) and were not observed even in large 
cohort studies (9–11).
Nomenclature—While some DPYD variants have been assigned a star (*) allele, only a 
minority of known variants has such a designation. Furthermore, the (*) allele nomenclature 
is used for other drug metabolizing enzymes to designate haplotypes consisting of more than 
one variant. Due to the size of DPYD and the low frequency of most variants, reliable 
haplotype inference across the entire gene is not possible. Therefore, the preferred 
nomenclature for DPYD variants is the use of Human Genome Variation Society (HGVS) 
nomenclature or rsID (see Supplement for further details).
Genetic Test Interpretation
Evidence supporting DPD function associated with known DPYD variants is summarized in 
the DPYD Allele Functionality Table (4). The relationship between DPYD genotype and 
phenotype has only been clearly established for a few variants, whereas the functional 
impact of many rare variants has been only assessed in vitro. Thus, the DPYD Allele 
Functionality Table (4) was divided into sections according to the strength of evidence 
supporting the assigned allele function: Strong evidence supporting function (from both in 
vitro and clinical studies); moderate evidence supporting function (from in vitro and 
clinical/ex vivo studies); in vitro data only and/or limited clinical/ex vivo data supporting 
function; uncertain function (conflicting or insufficient evidence supporting function, 
currently not considered actionable). For each variant, an activity score similar to that 
described in (12) was applied: 1 for normal function, 0.5 for decreased function, and 0 for no 
function variants (including variants with minimal DPD activity).
Table 1 summarizes the likely DPD phenotype based on genotype. The DPD phenotype is 
assigned a gene activity score (DPYD-AS), calculated as the sum of the activity scores of 
two DPYD variants with the lowest variant activity score (based on the DPYD Allele 
Functionality Table (4)). Briefly, carriers of two no function variants are classified as DPYD 
poor metabolizers (DPYD-AS: 0); carriers of one no function or decreased variant are 
considered DPYD intermediate metabolizers (DPYD-AS: 1 or 1.5), and those with only 
normal function variants are classified as DPYD normal metabolizers (DPYD-AS: 2). If two 
different decreased/no function variants are present, they are presumed to be on different 
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gene copies. Irrespective of the presence of decreased/no function variants, patients may 
carry multiple normal function variants. Common normal function variants may be located 
on the same gene copy as other normal function variants or decreased/no function variants 
(see Supplement for further details).
To ensure correct test interpretation for the transversion variants c.1129–5923C>G and c.
2846A>T, the strand to which alleles are assigned needs to be considered. In this guideline, 
allele designations are relative to the coding DNA reference sequence (NM_000110.3) and 
thus the decreased function (i.e., minor) alleles are c.1129–5923G and c.2846T, respectively.
Available Genetic Test Options
Testing options for DPYD genotype range from targeted analysis of selected variants to 
resequencing of the complete coding regions. In the context of 5-fluorouracil toxicity, at 
present, most tests focus on the four most common and well-established risk variants (c.
1905+1G>A, c.1679T>G, c.2846A>T, c.1129–5923C>G) or a subset thereof. Additional 
information about commercially available genetic testing options can be found at the 
Genetic Testing Registry website (http://www.ncbi.nlm.nih.gov/gtr/).
Incidental Findings
Individuals who harbor one copy of a no function DPYD variant can be considered to have 
carrier status for an inborn error of metabolism and consideration should be given to its 
potential effects on offspring. Patients homozygous for inactivating variants of DPYD have 
complete dihydropyrimidine dehydrogenase deficiency, a clinically heterogeneous 
autosomal recessive disorder of pyrimidine metabolism that shows wide variability of 
clinical presentations, ranging from no symptoms to severe convulsive disorders with motor 
and mental retardation (13, 14).
Other Considerations
Some of the testing options for 5-fluorouracil toxicity also include testing for other gene 
variants in TYMS and MTHFR. To date, however, the clinical utility of these genotypes is 
unclear (see further details in Supplement), and predictive dosing strategies have yet to be 
successfully applied. For a summary of pharmacogenomic studies of 5-fluorouracil, see the 
PGx Research tab at http://www.pharmgkb.org/drug/PA128406956.
There are alternative or complementary tests to DPYD genotyping that assess DPD activity 
directly in peripheral mononuclear cells or indirectly through the endogenous dihydrouracil/
uracil ratio (UH2/U) in plasma, or using a uracil loading test (15). See (16) for a review of 
these methods. The application of a combined genotype/phenotype approach including 
selected DPYD risk variants has been shown to reduce toxicity in a prospective study (17). 
However, such tests are not widely available. Furthermore, the mean and range of the pre-
therapeutic endogenous UH2/U ratio varied widely between studies, limiting its practical 
use, and several studies did not observe a strong correlation between the UH2/U ratio and 5-
fluorouracil plasma concentrations (18).
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The fluoropyrimidines 5-fluorouracil and capecitabine are widely used in the treatment of 
solid tumors including colorectal and breast cancer, and cancers of the aerodigestive tract. 
Each year, over 2 million patients are newly diagnosed with tumors that are commonly 
treated with fluoropyrimidines, mostly in combination with other antineoplastic drugs (19). 
Approximately 10–40% of fluoropyrimidine-treated patients develop severe and sometimes 
life-threatening toxicity (neutropenia, nausea, vomiting, severe diarrhea, stomatitis, 
mucositis, hand-foot syndrome) (7, 11, 20).
5-fluorouracil has a narrow therapeutic window resulting in a small difference between 
minimum efficacious and maximum tolerable dose. Only 1–3% of the administered 5-
fluorouracil is metabolized to cytotoxic metabolites with approximately 80% of the 
administered dose being degraded and the rest excreted in the urine. DPD is the first and 
rate-limiting step in the catabolic pathway converting 5-fluorouracil to dihydrofluorouracil 
(DHFU) (for further details see the 5-fluorouracil pathway at http://www.pharmgkb.org/
pathway/PA150653776). DPD levels show high inter- and intra-individual variation, which 
influences 5-fluorouracil exposure (21). Reduced activity of DPD results in reduced 
clearance and increased half-life of 5-fluorouracil, and can cause profound dose-related 
toxicities (22, 23). Capecitabine is a prodrug of 5-fluorouracil, being converted to 5-
fluorouracil and also metabolized by DPD. Therefore, toxic effects are similar in patients 
with decreased/no function DPYD variants (9, 24).
Linking Genetic Variability to Variability in Drug-related Phenotypes
There is substantial evidence linking DPYD genotype with variability in DPD enzyme 
activity, 5-fluorouracil clearance and 5-fluorouracil toxicity (summarized in Supplemental 
Table S1), which provides the basis for the dosing recommendations (Table 2).
In a meta-analysis combining data from eight cohort studies (n=7365 patients), the 
association of four DPYD variants with severe fluoropyrimidine-related toxicity was 
demonstrated (20): c.1905+1G>A (*2A), c.2846A>T, c.1679T>G (*13), and c.1129–
5923C>G (HapB3) with relative risks for toxicity of 2.9 (95%CI: 1.8–4.6), 3.0 (2.2–4.1), 4.4 
(2.1–9.3), and 1.6 (1.3–2.0), respectively. For all of these variants, an impact on DPD 
activity (assessed in PBMCs or using the UH2/U ratio) has been shown ((6); Supplemental 
Table S1). The strongest impact on DPD activity was observed for c.1905+1G>A and c.
1679T>G with a 50% and 68% reduction in heterozygous carriers, respectively (6). A 
moderate reduction in DPD activity was observed in heterozygous carriers of c.2846A>T 
and c.1129–5923C>G (30% and 35% reduced activity, respectively) (6). Two homozygous 
carriers of c.1129–5923C>G had 41% and 55% DPD activity compared to controls, 
consistent with a partial DPD deficiency (25). Homozygous expression in vitro resulted in 
dramatically reduced DPD activity (<25% of wild-type activity) for c.1905+1G>A and c.
1679T>G, and in reduced DPD activity (39–59% of wild-type activity) for c.2846A>T (26, 
27). In heterozygous carriers of c.1905+1G>A, c.2846A>T, and c.1679T>G, 5-fluorouracil 
clearance was reduced by 40–80% compared to non-carriers (23, 28). For heterozygous 
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carriers of c.557A>G (p.Y186C), commonly observed in individuals of African ancestry, a 
46% reduction in PBMC DPD activity compared to non-carriers was observed (29).
Prescribing Recommendations
Table 2 summarizes the genetics-based dosing recommendations for fluoropyrimidines using 
the calculated DPYD activity score (DPYD-AS). The strength of the prescribing 
recommendations is based on the known impact of some variants (c.1905+1G>A, c.
1679T>G, c.2846A>T, c.1129–5923C>G) on DPD activity, the demonstrated relationship 
between DPD activity and 5-fluorouracil clearance, and between 5-fluorouracil exposure and 
its toxic effects. Patients who are heterozygous for DPYD decreased/no function variants 
demonstrate partial DPD deficiency and should receive reduced starting doses. Prospective 
genotyping of c.1905+1G>A followed by a 50% dose reduction in heterozygous carriers 
resulted in a rate of severe toxicity comparable to non-carriers (30). This study thus 
demonstrated that DPYD genetic testing can reduce the occurrence of severe 
fluoropyrimidine-related toxicity, and that a dose reduction of 50% is suitable for 
heterozygous carriers of no function variants (DPYD-AS: 1). For decreased function 
variants, evidence is limited regarding the optimal degree of dose reduction. For c.2846A>T, 
a small retrospective study observed that the average capecitabine dose in heterozygous 
carriers was reduced by 25% compared to non-carriers (24). In a small prospective study, 
five patients carrying c.1236G>A (proxy for c.1129–5923C>G) were safely treated with a 
25% reduced capecitabine starting dose (31). This suggests that heterozygous carriers of 
decreased function variants (DPYD-AS: 1.5) may tolerate higher doses compared to carriers 
of no function variants (DPYD-AS: 1). In patients with DPYD-AS of 1.5, the individual 
circumstances of a given patient should therefore be considered to determine if a more 
cautious approach (50% starting dose followed by dose titration), or an approach 
maximizing potential effectiveness with a potentially higher toxicity risk (25% dose 
reduction) is preferable. Of note, both studies indicating the suitability of a 25% dose 
reduction in decreased function variant carriers included only patients receiving capecitabine 
and no data are currently available for infusional 5-fluorouracil.
Given that some patients carrying decreased or no function variants tolerate normal doses of 
5-fluorouracil, to maintain effectiveness, doses should be increased in subsequent cycles in 
patients experiencing no or clinically tolerable toxicity in the first two chemotherapy cycles 
or with subtherapeutic plasma concentrations. Similarly, doses should be decreased in 
patients who do not tolerate the starting dose.
In DPYD poor metabolizers (DPYD-AS: 0.5 or 0), it is strongly recommended to avoid use 
of 5-fluorouracil containing regimens. However, if no fluoropyrimidine-free regimens are 
considered a suitable therapeutic option, 5-fluorouracil administration at a strongly reduced 
dose combined with early therapeutic drug monitoring may be considered for patients with 
DPYD-AS of 0.5. It should be noted, however, that no reports of the successful 
administration of low dose 5-fluorouracil in DPYD poor metabolizers are available to date. 
Assuming additive effects of decreased and no function alleles (DPYD-AS: 0.5), it is 
estimated that a dose reduction of at least 75% would be required (i.e., starting dose <25% 
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of normal dose). Furthermore, in such cases, a phenotyping test (see Gene: DPYD – Other 
Considerations) is advisable to estimate DPD activity and a starting dose.
The U.S. Food and Drug Administration (FDA) and the Health Candida Sante Canada 
(HCSC) have added statements to the drug labels for 5-fluorouracil and capecitabine that 
warn against use in patients with DPD deficiency, and prescribing recommendations for 5-
fluorouracil, capecitabine, and tegafur are also available from the Dutch Pharmacogenetics 
Working Group (32).
Tegafur—Tegafur (not available in the United States), is a prodrug of 5-fluorouracil 
administered in combination with uracil (UFT) or with gimeracil and oteracil (S-1, 
Teysuno). For these therapies, evidence regarding the impact of DPYD variants on toxicity 
risk is very limited. Given the inhibition of DPD by the co-administered uracil or gimeracil, 
dose requirements of patients carrying decreased/no function DPYD variants are currently 
unknown. The dosing recommendations provided here currently apply only to 5-fluorouracil 
and capecitabine. As such, tegafur is rated as a CPIC “no recommendation” (see Supplement 
for definition).
Pediatrics—At the time of this writing, data on the possible role of DPYD genetic 
variation in 5-fluorouracil toxicity in pediatric patient populations is extremely scarce; 
however, there is no evidence to suggest that 5-fluorouracil pharmacokinetics differ from 
adult patients (33), and thus no evidence that DPYD variants would affect 5-fluorouracil 
metabolism differently in children.
Recommendations for Incidental Findings
Symptoms of DPD deficiency generally present in childhood and in the majority of patients, 
within the first year of life. Currently, a correlation between symptom severity and DPD 
function and/or genetics has not been established. However, early phenotypic (e.g., urine 
screening of uracil and its degradation products) and/or genetic testing (pre- or postnatal) of 
offspring of DPYD no function variant carriers could aid in early diagnosis (14) to avoid a 
lengthy diagnostic odyssey.
Other Considerations
Recently, a common polymorphism (rs895819A>G) in the DPYD-regulatory microRNA 
miR-27a was associated with lower DPD activity (34) and with fluoropyrimidine-related 
toxicity in patients carrying decreased function DPYD variants (35, 36). This suggests that 
this MIR27A variant may allow further stratification of DPYD risk variant carriers. 
However, pharmacokinetic studies combining DPYD and MIR27A genotype are needed 
before dosing recommendations that incorporate MIR27A genotype can be made.
Other genetic variation and patient characteristics such as sex and age have also been 
associated with 5-fluorouracil toxicity; however, the clinical utility of these associations are 
not fully understood (see Supplement for more information). Disease and treatment 
regimens may influence the overall risk of toxicity, and thus also the absolute risk of toxicity 
in carriers of DPYD decreased/no function variants. However, the association of DPYD 
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variants with 5-fluorouracil related toxicity has been found to be fairly consistent across 
treatment regimens (9, 20).
Pharmacokinetically-guided dosing of 5-fluorouracil has been shown to result in an increase 
in the proportion of patients with 5-fluorouracil exposure (AUC) within the targeted 
therapeutic range and a reduced number of 5-fluorouracil related adverse effects (37–39). In 
particular, to avoid underdosing of patients with genotype-based dose reductions who 
tolerate higher 5-fluorouracil doses, follow-up therapeutic drug monitoring is recommended.
Implementation of this guideline—The guideline supplement contains resources that 
can be used within electronic health records (EHRs) to assist clinicians in applying genetic 
information to patient care for the purpose of drug therapy optimization (see Resources to 
incorporate pharmacogenetics into an electronic health record with clinical decision support 
sections of the Supplement).
POTENTIAL BENEFITS AND RISKS FOR THE PATIENT
The benefit of DPYD genotyping has been demonstrated in a prospective study, which 
showed a reduced occurrence of severe 5-fluorouracil related toxicity and no toxicity-related 
deaths in carriers of c.1905+1G>A after genotype-guided dose reduction (30). Conversely, 
not all carriers of DPYD decreased/no function variants develop severe toxicity at standard 
doses (20, 28). As a consequence, some carriers of such variants may not receive the full 
benefit of fluoropyrimidine therapy with the recommended dose reductions. To maintain 
efficacy, it is important to increase the dose in patients experiencing no or clinically tolerable 
toxicity or with subtherapeutic 5-fluorouracil plasma concentrations. Patients who proceed 
with 5-fluorouracil therapy may still experience acceptable lower grade toxicity that may 
even be necessary in order to achieve efficacy. A possible risk is the misreporting or 
misinterpretation of genetic test results.
CAVEATS: APPROPRIATE USE AND/OR POTENTIAL MISUSE OF GENETIC 
TESTS
The presence of decreased or no function variants does not always result in toxicity. Overall, 
approximately 50% of decreased function DPYD variant carriers develop severe 5-
fluorouracil-related toxicity with lower doses (20, 28, 40), with estimates varying depending 
on the overall frequency of toxicity for a given treatment regimen and the number of 
treatment cycles evaluated (7, 11, 28, 40, 41). At the same time, patients without a DPYD 
decreased/no function variant may still experience severe toxicity due to other genetic, 
environmental or other factors.
The sensitivity of DPYD genetic testing depends on the number of variants investigated. By 
combining the DPYD variants c.1905+1G>A, c.2846A>T, c.1679T>G, c.1129–5923C>G, 
20–30% of early-onset 5-fluorouracil toxicities can be explained (7). However, a test that 
includes only a subset of those DPYD variants (e.g. only c.1905+1G>A) has a reduced 
sensitivity. Finally, given the existence of many additional rare deleterious DPYD variants, a 
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genetic test investigating only selected decreased/no function variants does not fully rule out 
DPD defects.
DISCLAIMER
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert 
consensus based on clinical evidence and peer-reviewed literature available at the time they 
are written and are intended only to assist clinicians in decision making and to identify 
questions for further research. New evidence may have emerged since the time a guideline 
was submitted for publication. Guidelines are limited in scope and are not applicable to 
interventions or diseases that are not specifically identified. Guidelines do not account for 
individual variations among patients and cannot be considered inclusive of all proper 
methods of care or exclusive of other treatments. It remains the responsibility of the health-
care provider to determine the best course of treatment for a patient. Adherence to any 
guideline is voluntary, with the ultimate determination regarding its application to be made 
solely by the clinician and the patient. CPIC assumes no responsibility for any injury or 
damage to persons or property arising out of or related to any use of CPIC’s guidelines, or 
for any errors or omissions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Assignment of likely DPD phenotypes based on DPYD genotypes
Likely Phenotype Activity Scorea Genotypesb Examples of genotypesc
DPYD Normal Metabolizer 2 An individual carrying two 
normal function alleles
c.[=];[=], c.[85T>C];[=], c.[1627A>G];[=]
DPYD Intermediate Metabolizer 1 or 1.5 An individual carrying one 
normal function allele plus 
one no function allele or one 
decreased function allele, or 





DPYD Poor Metabolizer 0 or 0.5 An individual carrying two 
no function alleles or an 
individual carrying one no 






Calculated as the sum of the two lowest individual variant activity scores. See text for further information.
b
Allele definitions, assignment of allele function and references can be found on PharmGKB (DPYD Allele Functionality Table (4))
c
HGVS nomenclature using the reference sequence NM_000110.3
d
Likely HapB3 causal variant. See DPYD Allele Functionality Table (4) for other HapB3 proxy SNPs.
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Table 2
Recommended Dosing of fluoropyrimidinesa by DPD phenotype
Phenotype Implications for 
Phenotypic Measures
Dosing Recommendations Classification of Recommendationsb
DPYD Normal Metabolizer Normal DPD activity 
and “normal” risk for 
fluoropyrimidine 
toxicity
Based on genotype, there is no 
indication to change dose or therapy. 
Use label-recommended dosage and 
administration.
Strong
DPYD Intermediate Metabolizer Decreased DPD 
activity (leukocyte 
DPD activity at 30% 
to 70% that of the 
normal population) 
and increased risk for 
severe or even fatal 




Reduce starting dose based on activity 
score followed by titration of dose 
based on toxicityc or therapeutic drug 
monitoring (if available).
Activity score 1: Reduce dose by 50%
Activity score 1.5: Reduce dose by 
25% to 50%
Activity score 1: Strong
Activity score 1.5: Moderate
DPYD Poor Metabolizer Complete DPD 
deficiency and 
increased risk for 
severe or even fatal 




Activity score 0.5: Avoid use of 5-
fluorouracil or 5-fluorouracil prodrug-
based regimens
In the event, based on clinical advice, 
alternative agents are not considered a 
suitable therapeutic option, 5-
fluorouracil should be administered at 
a strongly reduced dosed with early 
therapeutic drug monitoring.e
Activity score 0: Avoid use of 5-






Rating scheme described in Supplement.
c
Increase the dose in patients experiencing no or clinically tolerable toxicity in the first two cycles to maintain efficacy; decrease the dose in 
patients who do not tolerate the starting dose to minimize toxicities.
d
If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping 
data, a dose of <25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance.
e
Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately 
discontinue the infusion if the drug level is too high.
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